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Summary
Background Tens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through 
post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. 
Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic 
countries due to high costs, poor access, and supply.
Methods We developed epidemiological and economic models to investigate the effect of an investment in post-exposure 
prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with 
improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and 
with and without dog vaccination. We took the health provider perspective, including only direct costs.
Findings We predict more than 1 million deaths will occur in the 67 rabies-endemic countries considered from 2020 to 
2035, under the status quo. Current post-exposure prophylaxis use prevents approximately 56 000 deaths annually. 
Expanded access to, and free provision of, post-exposure prophylaxis would prevent an additional 489 000 deaths 
between 2020 and 2035. Under this switch to efficient intradermal post-exposure prophylaxis regimens, total projected 
vaccine needs remain similar (about 73 million vials) yet 17·4 million more people are vaccinated, making this an 
extremely cost-effective method, with costs of US$635 per death averted and $33 per disability-adjusted life-years 
averted. Scaling up dog vaccination programmes could eliminate dog-mediated rabies over this time period; improved 
post-exposure prophylaxis access remains cost-effective under this scenario, especially in combination with patient 
risk assessments to reduce unnecessary post-exposure prophylaxis use.
Interpretation Investing in post-exposure vaccines would be an extremely cost-effective intervention that could 
substantially reduce disease burden and catalyse dog vaccination efforts to eliminate dog-mediated rabies.
Funding World Health Organization.
Copyright © This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited.  In any use of this article, 
there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO 
logo is not permitted. This notice should be preserved along with the article’s original URL.
Introduction
Timely post-exposure prophylaxis prevents the fatal onset 
of rabies, which causes an estimated 60  000 human 
deaths each year, mostly in Africa and Asia and among 
children.1,2 Domestic dogs are responsible for 99% of 
human cases.3 Although mass dog vaccination is required 
for elimination of dog-mediated rabies, the disease 
burden could be substantially reduced through improved 
access to post-exposure prophylaxis.
WHO recommendations for rabies post-exposure 
prophylaxis have been updated in line with new evidence.4 
Procedures depend on the type of contact with the suspect 
rabid animal, with administration of rabies immunoglobulin 
recommended for high-risk exposures. Intradermal 
multisite vacci nation regimens have been developed, which 
are more economical than intra- muscular administration 
because they use reduced vaccine volumes.4 While the use 
of post-exposure prophylaxis at current levels saves many 
lives,2 access to post-exposure prophylaxis is poor in many 
parts of the world, particularly rural areas where most rabies 
exposures occur. Even if people who have been bitten get to 
a treatment centre and post-exposure prophylaxis is 
available, its cost is often unaffordable.
A global framework to reach zero human deaths from 
dog-mediated rabies by 2030 was developed by WHO and 
partners in 2015.3 A strategic plan covering human 
and animal vaccine demand was developed for the 
implementation of this framework.5 In 2016, WHO 
established a Strategic Advisory Group of Experts Working 
Group on rabies vaccines and rabies immunoglobulins,6 
aiming to increase the public health effect of rabies 
biologics through practical and feasible recommendations. 
This effort resulted in a recommendation of a dose-
sparing abridged 1-week intradermal regimen, requiring 
only three clinic visits, and guidance for more prudent use 
of rabies immunoglobulin.4
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Enhancing access to rabies post-exposure prophylaxis 
was considered by Gavi, the Vaccine Alliance, in their 
vaccine investment strategy in 2008 and 2013.7 In 2013, 
post-exposure prophylaxis was estimated to avert almost 
200 000 future deaths between 2015 and 2030 at a low 
cost per death averted, and that investment could 
stimulate the shift to more economical intradermal 
vaccination.7 However, knowledge gaps were recognised 
and observational studies were recommended to 
reduce uncertainties about implementation feasibility. 
Subsequently, Gavi supported field studies on rabies 
burden, treatment seeking, post-exposure prophylaxis 
compliance, and vaccine efficacy as part of their learning 
agenda. Gavi will reconsider the rabies vaccine invest-
ment case in December, 2018.
We model the epidemiological and economic effect of 
changes in policy and practice for the provision of post-
exposure prophylaxis, which Gavi investment could 
support.
Methods
Given inadequate rabies surveillance, studies of human 
rabies deaths rely upon model-derived estimates.8 We use 
an economic model of post-exposure prophylaxis demand 
linked to an epidemiological model characterising rabies 
dynamics in domestic dog populations (the primary 
reservoir).
We included countries that are currently (n=46), or have 
ever been, Gavi-eligible (n=67) and are endemic for rabies 
(appendix), henceforth denoted as Gavi-46 and Gavi-67. We 
did all analyses using R version 3.4.1. We used GATHER9 
and CHEERS10 checklists to improve reporting quality 
(appendix).
Economic model
We adopted the static decision tree (characterised in 
figure 1; appendix), informed by literature-derived para-
meter estimates and available data.
Research in context
Evidence before this study
We searched PubMed for papers published from Jan 1, 1980, 
to May 31, 2018, with the terms “rabies” AND “burden” AND 
(“global” OR “Africa” OR “Asia”) and identified two previous 
modelling studies that suggested around 60 000 deaths from 
rabies occur each year. Post-exposure prophylaxis after a 
suspected rabies exposure is a safe and effective way of 
preventing human deaths from rabies and has long been 
promoted by WHO. However, human deaths from rabies remain 
high in many low-income and middle-income countries 
because access to post-exposure prophylaxis is poor. Although 
mass dog vaccination is required for elimination of 
dog-mediated rabies, improved provision and use of 
post-exposure prophylaxis would also prevent deaths. 
Dose-sparing intradermal vaccine regimens are known to be 
much more economical than intramuscular regimens but 
have not been adopted everywhere.
Added value of this study
This is the first paper to consider the effect of an investment in 
rabies post-exposure prophylaxis across all 67 countries that 
are, or have previously been, Gavi-eligible and where rabies is 
endemic. Although data are still scarce in many areas, we used 
information from studies supported by the Gavi learning 
agenda. Improving provision of rabies vaccines for 
post-exposure prophylaxis is a highly cost-effective 
intervention that could prevent an additional 489 000 deaths 
from rabies from 2020 to 2035. Our analyses suggest that 
investments should prioritise vaccines for post-exposure 
prophylaxis rather than rabies immunoglobulin, which is costly 
and has more marginal health benefits. Even with expanding 
dog vaccination efforts and associated reductions in the risk 
of human exposure over the 2020–35 time period, improved 
access to post-exposure prophylaxis remains a highly 
cost-effective intervention.
Implications of all the available evidence
Increasing timely access to rabies vaccines for post-exposure 
prophylaxis, free at point-of-care, would save many lives, is 
highly cost-effective, and is feasible under the current vaccine 
production capacity, with the switch to the dose-sparing 
abridged 1-week intradermal regimen. In combination with 
scaled-up mass dog vaccination, an investment to improve 
access to post-exposure prophylaxis could be transformative 
for rabies prevention and could catalyse the global campaign 
Zero by 30 to eliminate human deaths from dog-mediated 
rabies.
Dog bite Health facility PEP Rabies riskDogs
Rabid
Costs 
No health seeking
PEP late or
incomplete
PEP not received
Healthy
No health seeking
PEP not received
High risk 
High cost
Figure 1: Decision tree covering rabies exposure, health seeking, and health outcomes, including death due to 
rabies or prevention through PEP
PEP provided to individuals bitten by healthy animals results in costs but does not avert deaths. For the full 
decision tree, see appendix. PEP=post-exposure prophylaxis.
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We took the perspective of the health provider 
and considered direct medical costs only. Currently, 
individuals bear post-exposure prophylaxis costs in many 
countries (appendix); with investment, post-exposure 
prophylaxis costs would be borne by Gavi with 
cofinancing from national governments. Health benefits 
were measured in terms of deaths and disability-adjusted 
life-years (DALYs) averted; rabies is universally fatal and 
we did not consider acute disability so DALYs are equal to 
years of life lost. Individuals in the model were aged 
0–99 years. The time horizon was 2020–35 and our 
analysis accounts for human population growth over this 
timescale. We converted all costs to US$, 2016, using 
inflation indicators (Consumer Price Index) from the 
World Bank. All scenarios were run with discounting at 
3% (0% as alternative). We calculated the cost per death 
and per DALYs averted and, as appropriate, incremental 
costs and benefits.
Epidemiological model
Human rabies exposures depend on dog rabies incidence 
and rabid dog biting behaviour. We used a stochastic 
dynamic transmission model to characterise rabies in dog 
populations accounting for the effect of mass dog 
vaccination. Coverage achieved wanes between vaccination 
campaigns because of turnover in the dog population, so 
we incorporate dog demography. We ignore wildlife, 
which have a negligible role in maintenance of canine 
rabies.11 We model an endemic scenario with and without 
mass dog vaccination to generate typical dog rabies 
incidence and trajectories to elimination (appendix).
Scenarios
We investigated the following scenarios (assumptions 
detailed in the panel): (1) status quo, with countries 
delivering post-exposure prophylaxis according to 
current provision rates and practices; (2) increased post-
exposure pro- phylaxis access, with free vaccination 
following the dose-sparing abridged 1-week intradermal 
regimen4 and improved health seeking, vaccine provision, 
and post-exposure prophylaxis completion, considering a 
base case (2a), low variant (2b), and high variant (2c); (3) 
as 2, with provision of rabies immunoglobulin, as per the 
latest recommendations;4 (4) declining incidence due to 
scaling up mass dog vaccination (currently negligible in 
most Gavi-eligible countries), with post-exposure 
prophylaxis provided according to the status quo (4a), 
with improved post-exposure prophylaxis access (4b with 
base case parameter values), and as with the previous 
point, with integrated bite case management (IBCM) to 
reduce unnecessary post-exposure prophylaxis for people 
bitten by healthy animals (4c).12,13
We simulated staggered implementation as described in 
the Global Strategic Plan Zero by 30 (appendix), assuming 
improved post-exposure prophylaxis access from 2020 
onwards for phase 1 countries (n=21), from 2022 for phase 
2 countries (n=33), and from 2026 for phase 3 countries 
(n=13). On implementation, we adjusted health seeking 
and post-exposure prophylaxis provision parameters and 
modelled incremental changes thereafter (panel).
Data sources
We developed a data template and sought information 
from multiple sources (appendix). Data from contact 
tracing and health-care use studies were obtained from 
partners in Tanzania, Madagascar, Sri Lanka, and Kenya. 
Partners in Chad, Côte d’Ivoire, Mali, Uganda, Haiti, 
Cameroon, Cambodia, Bhutan, Vietnam, Thailand, and 
the Philippines completed data templates. A systematic 
literature review of papers on the burden of rabies 
published from Jan 1, 2013, to Feb 28, 2017, was completed,2 
updating a previous review. Further country-specific 
Panel: Parameters and assumptions for modelling scenarios
We used biologically-defined constants for the probability of developing rabies following 
exposure, pinfect, and of post-exposure prophylaxis (PEP) preventing rabies, pprevent 
(appendix). Under the status quo (scenario 1) we used country-specific data from health 
facility use and Gavi Learning Agenda studies to inform parameters for health seeking and 
PEP provision (appendix gives country-specific estimates and gives cluster averages used 
when no country-specific data were available). In scenarios with improved PEP access 
(scenarios 2 and 3), we modelled increased health seeking, PEP provision, and 
compliance, as detailed here, according to timelines from the Global Strategic Plan 
(appendix). Dog vaccination is modelled in scenario 4, with Integrated Bite Case 
Management (IBCM) to reduce unnecessary PEP use for persons bitten by healthy dogs 
included in scenario 4c. 
pseek|rabid
Probability: seeking care when bitten by suspect rabid dog.
Change with improved PEP access: initial increase of 0·1 from status quo in scenario 2a, 
base case (0·05 increase in scenario 2b low variant, 0·15 in scenario 2c high variant), 
with 0·03 increase per year thereafter to a cap of 0·9 in the base case (0·85 in scenario 2b, 
0·95 in scenario 2c)
pseek|healthy
Probability: seeking care when bitten by healthy dog.
Change with improved PEP access: initial increase of 0·1 from status quo in scenario 2a, 
base case (0·05 increase in scenario 2b, 0·15 in scenario 2c), to a cap of 1 in all scenarios; 
no incremental increases after introduction.
preceive
Probability: receiving PEP if treatment sought.
Change with improved PEP access: initial increase of 0·1 from status quo in scenario 2a, 
base case (0·05 examined as a scenario 2b and 0·15 as a scenario 2c), with 0·03 increase per 
year thereafter to a cap of 0·93 base case (0·88 scenario 2b, 0·98 scenario 2c). Under 
scenario 4c with IBCM, preceive was reduced to 0·5 for healthy dog bites on implementation 
of the intervention and was reduced further to 0·1 after elimination (zero dog 
rabies cases).
pcomplete
Probability: completing regimen.
Change with improved PEP access: initial increase of 0·1 in scenario 2a, base case 
(0·05 in scenario 2b, 0·15 in scenario 2c), with 0·03 increase per year thereafter to a cap of 
0·8 base case (0·75 scenario 2b, 0·85 scenario 2c).
For the Consumer Price Index 
see https://data.worldbank.org/
indicator/FP.CPI.TOTL
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searches (“country” AND “rabies”) in PubMed were 
completed in July 26, 2017. Subsequent relevant pub-
lications were also reviewed where identified. Surveys of 
post-exposure prophylaxis provision were done by WHO 
and the US Centers for Disease Control and Prevention for 
23 countries (15 of which were Gavi-eligible countries in 
2018), covering vaccine administration route, regimen, 
cost, access, procurement, distribution, and monitoring. 
Follow-up by WHO ascertained whether patients in other 
countries pay for vaccines or are provided post-exposure 
prophylaxis free-of-charge from government clinics 
(appendix). We assumed that countries without 
information charged patients. Country-specific dog 
populations were esti- mated from human-to-dog ratios.1 
Human population estimates and life expectancies for 
each country were taken from UN World Population 
Prospects 2017, medium variant.14 The proportions of 
populations in urban and rural environments were taken 
from the World Bank development indicators.15 Published 
age distributions of rabies cases were used.1 We calculated 
a less conservative set of DALYs based on WHO frontier 
life expectancy in 2030.16 Health-care costs (ie, health 
worker time for post-exposure prophylaxis delivery) by 
country were obtained from WHO-CHOICE estimates.17
Model parameters
We assigned countries to a geographical cluster and we 
calculated cluster parameter values as the mean of 
country values in the cluster (appendix). Where country-
specific parameters were not available or data were 
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Figure 2: DALYs (undiscounted; A), deaths (undiscounted; B), cost per DALYs averted (discounted; C), and cost per death averted (discounted; D) from 2020 
to 2035 under the modelled scenarios
Estimated outcomes presented with 95% PIs. Estimates do not include costs of dog vaccinations and only show the cost-effectiveness of PEP incremental to dog 
vaccination. Costs of IBCM are assumed to be covered by introductory grants (together with improved PEP access). Modelling assumptions are shown in panel and 
results in appendix. Only the base case is shown for scenario 2—ie, scenario 2a base case. DALYs=disability-adjusted life-years. IBCM=integrated bite case 
management. PEP=post-exposure prophylaxis. PI=prediction interval. RIG=rabies immunoglobulin. S=scenario. Vax=vaccination. 
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judged to be poor quality or inappropriate (eg, small 
numbers, biased sampling), we used cluster values.
Several parameters were considered biologically 
determined and were not expected to vary (appendix). We 
used reported estimates of the probability of infection 
following exposure (pinfect), of complete and timely post-
exposure prophylaxis (pprevent1), or incomplete or late post-
exposure prophylaxis (pprevent2) preventing infection.18 For 
Ethiopia, where less effective nerve tissue vaccines are 
used, we used published data to estimate the probability 
that complete (pprevent3) or incomplete nerve tissue vaccine 
use (pprevent4) prevents infection.19
To capture rabies exposures, we multiplied dog rabies 
incidence by a per-capita transmission probability and 
national dog population estimates (appendix). This 
calculation assumes only a fraction of rabid dogs bite 
people (on average 0·38 people are bitten per rabid dog;20 
appendix). Using incidence data from multiple countries 
of patients who have been bitten, we estimated the 
proportion of rabid versus healthy animals and baseline 
health-seeking probabilities following rabid and healthy 
dog bites (pseek|rabid, pseek|healthy; appendix).
Post-exposure prophylaxis delivery
We estimated post-exposure prophylaxis use for each 
scenario. Vials of rabies immunoglobulin and vaccines 
for intradermal use contain multiple doses but opened 
vials must be discarded at the end of the day. A modelling 
analysis informed our assumptions for projected vial 
sharing under different clinic throughputs.21 We assumed 
use of 1 mL vials with an average of 2·2 vials per complete 
1-week intradermal post-exposure prophylaxis in rural 
settings, 0·67 vials per complete post-exposure pro-
phylaxis in urban settings, and 1·47 vials per incomplete 
post-exposure prophylaxis in rural settings and 0·45 vials 
in urban settings (ie, <three visits; appendix).
Immunoglobulin use in virtually all Gavi-eligible 
countries is negligible (with some notable exceptions—
eg, Sri Lanka, India, and Bhutan); therefore, it was not 
included in the status quo. In scenario 3, we assume 
administration of rabies immunoglobulin only in urban 
clinics, and then only to high-risk patients—ie, with 
multiple or deep bites, bites to the head or hands, bites 
by confirmed rabid dogs, or to immunocompromised 
patients. Around 15% of patients fit these criteria from 
reviews of clinic data from different countries. We 
modelled 0·32 rabies immunoglobulin vials per patient 
on average (appendix).21
We used reported costs of post-exposure prophylaxis 
(appendix) to model the status quo and assumed that 
upon Gavi investment, rabies vaccine would be 
purchased for $5 per vial and rabies immunoglobulin at 
$45 per vial (similar to current prices of equine-derived 
immunoglobulin from the Pan American Health 
Organization revolving fund). We assumed fixed 
introductory costs of $100 000 per country to facilitate 
training and implementation of improved post-exposure 
prophylaxis access.
Sensitivity analysis
We examined the effect of different parameters with 
one-way sensitivity analyses. For the principal model 
outputs, we ran a probabilistic sensitivity analysis taking 
1000 draws from the parameter distributions (based on 
95% CIs) to generate a 95% prediction interval (PI) and 
mean central estimate. We examined the sensitivity of 
results to uncertainty in parameters in the epidemiological 
model separately (appendix). Because the future price of 
post-exposure prophylaxis is unknown, we did not 
include it in the probabilistic sensitivity analysis, but we 
investigated vaccine costs of $10 and $2·5 per vial and 
rabies immunoglobulin costs of $20 per vial. We 
increased the introductory costs to $500 000 given the 
uncertain costs of scaling up post-exposure prophylaxis, 
since studies on vaccine introduction indicate that such 
grants might underestimate true costs.22
Role of the funding source
The sponsor of the study (WHO) supported a meeting of 
the Rabies Modelling Consortium and WHO employees 
(BA-R and LK) contributed to study design, data 
collection, interpretation, and writing. The corresponding 
Scenario 1: status quo 
(95% PI)
Scenario 2a, base case: 
improved PEP access (95% PI)
Scenario 2b: low variant 
(95% PI) 
Scenario 2c: high variant 
(95% PI) 
Rabies deaths 1·07 (0·852–1·32) 0·576 (0·453–0·711) 0·720 (0·561–0·885) 0·425 (0·333–0·522)
Rabies deaths averted 0·898 (0·704–1·11) 1·39 (1·09–1·72) 1·25 (0·971–1·54) 1·55 (1·22–1·90)
DALYs 52·1 (41·4–64·3) 27·9 (21·9–34·5) 34·9 (27·2–43·0) 20·5 (16·1–25·2)
DALYs averted 44·2 (34·7–54·6) 68·0 (53·3–84·3) 61·1 (47·6–75·5) 75·7 (59·7–93·0)
Vaccine vials used 73·5 (65·7–81·4) 73·8 (66·1–81·6) 62·2 (55·9–68·8) 86·8 (77·7–96·2)
PEP courses initiated 27·8 (24·6–31·0) 45·2 (40·5–50·0) 38·2 (34·4–42·3) 52·8 (47·2–58·5)
PEP courses completed 19·8 (17·3–22·2) 35·1 (31·4–38·9) 28·2 (25·3–31·2) 43·4 (38·7–48·1)
Total cost (US$) 1140 (1100–1260) 1110 (1070–1220) 935 (902–1030) 1300 (1250–1430)
Data are outcome in millions (95% PI), unless otherwise specified. Equivalent information on other scenarios (3 and 4a–c) is presented in the appendix. PI=prediction interval. 
PEP=post-exposure prophylaxis. DALYs=disability-adjusted life-years.
Table: Model results across all Gavi-67 countries projected over 2020–35 for the different scenarios
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Figure 3: Projected outcomes 
under different scenarios 
over the 2020–35 time 
period
Estimated outcomes per year 
presented with 95% PIs. 
(A) Human deaths from rabies 
(× 1000); (B) people initiating 
courses of PEP (× 1000); 
(C) vials of vaccine (× 1000) 
required for all 67 countries 
(top) and for selected 
countries (Bangladesh, 
Ethiopia, Kenya, and 
Myanmar) according to the 
status quo (scenario 1), under 
improved PEP access 
(scenario 2, base case), and 
with improved access to PEP 
vaccines concomitant with 
mass dog vaccination 
(scenario 4b). The step 
changes correspond to the 
timing of improvements in 
access to PEP and introduction 
of dog vaccination 
programmes. Bangladesh, 
Ethiopia, and Kenya are all 
phase 1 countries 
(implementation in 2020) 
in the Global Strategic Plan 
(appendix), whereas Myanmar 
is a phase 2 country 
(implementation in 2022). 
PEP=post-exposure 
prophylaxis. PI=prediction 
interval. S=scenario. 
Vax=vaccination.
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authors had full access to all the data in the study and 
final responsibility for the decision to submit for 
publication.
Results
From 2020 to 2035, we estimate that under the status 
quo 1 074 000 dog-mediated rabies deaths (95% PI 
852 000–1 325 00) in humans will occur in the 67 endemic 
countries considered (figure 2; 580 000 deaths in Gavi-46 
countries)—around 67 000 deaths per year. Approximately 
106 000 (10%) of 1 074 000 deaths (84 200–131 000) are 
children younger than 5 years. Most deaths are in 
sub-Saharan Africa (347 000 in the east Africa cluster and 
231 000 in the west Africa cluster) and Asia (464 000), with 
much fewer in the Americas (33 000). Country-specific 
burden estimates are provided in the appendix. After 
standardising for population growth, our estimates of 
deaths are similar to previous estimates2 in most countries 
(appendix). Current levels of post-exposure prophylaxis 
prevent approximately 56 000 deaths or 2 764 000 DALYs 
per year.
With improved post-exposure prophylaxis access 
(scenario 2; base case) projected annual deaths and DALYs 
more than halved from 2020 to 2035 (table), equating to a 
total of 1 388 000 deaths averted or 68 010 000 DALYs averted 
over this period. Bite victims initiating post-exposure 
prophylaxis from 2020 to 2035 increase from 27·8 million 
under the status quo to 45·2 million (figure 3) with 
improved post-exposure prophylaxis access. Switching to 
the dose-sparing abridged 1-week intradermal regimen 
means that overall vaccine demand does not change very 
much (stays around 73 million vials at a [undiscounted] 
cost of about $11·1 billion). Annual costs with improved 
access (scenario 2; base case) would be $69·2 million in 
Gavi-67 or $29·3 million in Gavi-46 countries (appendix). 
Under the status quo, costs of post-exposure prophylaxis 
are mainly borne by patients (48 of 67 countries). From 
2020 to 2035, assuming Gavi investment displaces personal 
but not government expenditure (appendix), $975·1 million 
(undiscounted costs) would be required to deliver improved 
access in all Gavi-67 countries and $403·7 million to 
Gavi-46 countries.
Projected vaccine requirements vary (figure 3 shows 
overall vaccine use, with four country-specific examples). 
Under improved post-exposure prophylaxis access, for 
example in Bangladesh, where intradermal regimens are 
used, vaccine demand incrementally increases, whereas 
in Kenya, where intramuscular regimens are used, 
vaccine requirements decrease because the same vaccine 
volume treats many more patients with intradermal 
vaccination. In Ethiopia, where nerve tissue vaccines are 
used, even larger reductions in vial use are expected.
Post-exposure prophylaxis prevents rabies at an average 
cost of $1021 per death averted and $52 per DALYs averted 
under the status quo (figure 2). With improved access, 
cost-effectiveness improves to $635 per death averted and 
$33 per DALYs averted in Gavi-67 countries and 
$605 per death averted and $32 per DALYs averted in 
Gavi-46 countries. Cost-effectiveness (appendix) varied 
geographically, and was lowest in Asia ($874 for deaths 
and $44 for DALYs) and highest in the Americas 
($266 and $13). Incremental to the status quo, investment 
to improve post-exposure prophylaxis access would be 
highly cost-effective, averting 494 700 additional deaths, 
while reducing expenditure by $32·5 million (incremental 
cost-effectiveness ratio [ICER] –$66 per death averted or 
–$7 per DALYs averted).
Conversely, improving access to rabies immunoglobulin 
(scenario 3), in addition to vaccination is costly, requiring 
an additional $76·2 million (95% PI $73·0–85·0 million) 
between 2020 and 2035. Only marginal health gains are 
achieved, with about 100 additional deaths prevented and 
high uncertainty, resulting in a high ICER of almost 
$666 000 per death averted.
Under scenario 4, we assumed scaled-up dog vacci- 
nation programmes reduces the incidence of rabies 
exposures and deaths (figures 2, 3) to 328 000 deaths and 
15 892 000 DALYs from 2020 to 2035. Improved access to 
post-exposure prophylaxis reduces the number of deaths 
to 266 000 and 12 847 000 DALYs, requiring 55·4 million 
vaccine vials from 2020 to 2035 (appendix) and remains 
cost-effective, albeit at a higher cost per death averted 
($2307) and DALYs averted ($47; figure 2). Incremental to 
dog vaccination, investment in post-exposure prophylaxis 
results in lower mean costs and greater mean benefits 
(figure 4). In the third part of scenario 4 (4c), IBCM 
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Figure 4: The cost-effectiveness plane showing the ICERs for dog vaccination scenarios
Under dog vaccination (scenarios 4a–c) improved PEP access (scenarios 4b and 4c) all have greater health benefits 
and similar or lower costs. The differences between clusters relate to the size of the populations at risk. 
ICER=incremental cost-effectiveness ratio. IBCM=integrated bite case management. PEP=post-exposure 
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targets post-exposure prophylaxis to cases identified as 
bitten by suspect rabid dogs, rather than indiscriminately 
(panel), thereby controlling post-exposure prophylaxis 
demand as rabies incidence declines. IBCM should 
therefore be encouraged under all scenarios. Post-
exposure prophylaxis requirements reduce to fewer than 
21·3 million vials during 2020–35 and cost-effectiveness 
increases even as elimination is approached (figure 2; 
appendix).
Estimates of the rabies burden and cost-effectiveness of 
interventions are most affected by uncertainty in the 
incidence of rabid dog bites and the probability that 
exposure results in infection (appendix). Uncertainty in 
transmission affects rabies incidence and burden, 
whereas demographic uncertainty has a negligible effect. 
Improved dog vaccination coverage coordinated across 
regions more rapidly controls rabies, reducing the burden 
(appendix). Refined dog population estimates would 
change the magnitude of estimates of rabies burden and 
post-exposure prophylaxis use, but conclusions remain 
consistent across a plausible range of parameter values.
DALYs based on WHO frontier life expectancy in 
2030 improved the overall cost per DALYs averted for 
scenario 2 from $33 to $30. Similar changes were 
observed for other scenarios.
Increasing vaccine vial costs from $5 to $10 increases 
the cost per death averted to $853, but post-exposure 
prophylaxis remains highly cost-effective. The ICER of 
rabies immunoglobulin exceeded $302 000 per death 
averted when vial costs were reduced from $45 to $20. 
Increasing the introductory grants to $500 000 did not 
affect our conclusions.
Discussion
The burden of dog-mediated rabies is considerable; from 
2020 to 2035 under the status quo, we estimate over 
1 million deaths will occur in the 67 countries considered. 
Although post-exposure prophylaxis saves many lives, 
improved access, free of cost at point-of-care, and following 
the latest WHO recommendations for intradermal 
vaccination,4 would avert 1 388 000 deaths (ie, an additional 
489 000 deaths) and 68 010 000 DALYs over this time 
period. This improvement in access is highly cost-effective 
at only $635 per death averted and $33 per DALYs averted 
and is feasible under current vaccine production with a 
switch to economical intradermal regimens through a 
Gavi investment. Interventions that avert one DALY for 
less than the national average annual per-capita income 
are considered highly cost-effective.23
Improving access to rabies immunoglobulin (mostly 
unavailable in rabies-endemic countries), in addition to 
vaccines, was not cost-effective. Benefits of rabies 
immunoglobulin were shown when used with nerve 
tissue vaccines,24 but this benefit is likely to be much less 
with the highly immunogenic purified cell culture and 
embryonated egg-based rabies vaccines recom mended 
nowadays.4 Reported deaths among patients who initiate 
post-exposure prophylaxis appear to be related to 
treatment delays and poor compliance,18,25 rather than a 
lack of rabies immunoglobulin availability.26 Investments 
to improve timely vaccine access are therefore likely to 
save many more lives than investment in rabies 
immunoglobulin.
WHO and partners launched the global strategic plan 
to end human deaths from dog-mediated rabies (Zero by 
30) to eliminate human deaths from dog-mediated rabies 
through both mass dog vaccination and improved access 
to post-exposure prophylaxis.5 Cost-effectiveness of 
post-exposure prophylaxis decreases as elimination of 
canine rabies approaches, because genuine exposures 
become increasingly rare, whereas precautionary post-
exposure prophylaxis provision con tinues. Nonetheless, 
our models suggest that in this context, improved access 
to post-exposure prophylaxis remains cost-effective (with 
a cost per DALYs averted less than gross domestic 
product per capita), particularly if implemented in 
conjunction with IBCM.12 Operational research on IBCM 
is warranted since it is a compelling strategy to curtail 
post-exposure prophylaxis demand while enhancing 
surveillance during the endgame.27
A major challenge for this study was the paucity of data 
available. Studies carried out in several rabies-endemic 
countries through the Gavi learning agenda allowed us to 
divide post-exposure prophylaxis demand by people bitten 
by healthy versus rabid animals, accounting for higher 
health seeking in wealthier settings, and variability driven 
by the size of dog populations. Because few dog population 
estimates were available, the accuracy of our projections 
are constrained, and results are notably sensitive to 
changes in health-seeking parameters. However, sensitivity 
analyses indicated that our conclusions regarding cost-
effectiveness were robust even under uncertainties.
We made several simplifying assumptions. We 
assumed no country-specific variation in vaccine wastage 
from discarding opened vials, only rural–urban variation 
(appendix). Vaccine used per post-exposure prophylaxis 
course plateaus at throughputs exceeding 30 new patients 
per month;21 therefore, cost-effectiveness is unlikely to be 
greatly underestimated in the most populated settings, 
nor substantially overestimated in rural populations, 
because we do not account for patient clustering from 
bites by the same animal. Our assumptions regarding 
improved post-exposure prophylaxis access are supported 
by increased health seeking, access, and compliance 
observed with the introduction of free post-exposure 
prophylaxis in several countries (appendix).18 We also 
assumed incremental improvements in health seeking 
by victims of rabid bites over time, consistent with Gavi 
projections (and as used in models of other vaccine 
programmes)28 and data from countries that have 
invested in post-exposure prophylaxis access and free 
provision (Bhutan, Philippines, Sri Lanka). We did not 
model sustained increases in health seeking by people 
bitten by healthy dogs (potentially expected with 
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heightened awareness associated with dog vaccination), 
thereby favouring the cost-effectiveness of improved 
post-exposure prophylaxis access. However, IBCM could 
reduce unnecessary post-exposure prophylaxis use and 
improve cost-effectiveness under all scenarios (we only 
modelled IBCM under dog vaccination, scenario 4c).12,13,20,29 
The effect and cost-effectiveness of post-exposure 
prophylaxis depends on current national strategies for 
provision (figure 3). We modelled these factors according 
to data gathered by WHO on post-exposure prophylaxis 
provision with timing aligned with the Global Strategic 
Plan. Although post-exposure prophylaxis access might 
be affected by spatial factors (eg, travel to clinics), we did 
not explicitly model this scenario, and instead assumed 
average improvements to access and provision (panel).
We applied our simulated trajectories of rabies incidence 
under dog vaccination irrespective of country, assuming 
1% rabies incidence in unvaccinated dog populations. Dog 
vaccination has repeatedly been shown to rapidly reduce 
incidence,30,31 although rabies often persists at low levels 
with incursions and localised wildlife reservoirs (not 
modelled here) hindering elimination.32 Moreover, 
socioeconomic factors influence progress by affecting the 
delivery of mass dog vaccination programmes.33 We 
assume coordinated implementation minimises incur-
sions, thereby generating optimistic timelines for 
elimination. However, estimates of post-exposure pro-
phylaxis requirements should not be greatly affected by 
this assumption given the considerable use of post-
exposure prophylaxis for people bitten by non-rabid 
animals.20 While we considered the cost-effectiveness of 
post-exposure prophylaxis in the context of dog vaccination, 
we did not model dog vaccination costs; previous studies 
have shown dog vaccination to be very cost-effective.29,34
In 2013, Gavi considered that rabies post-exposure 
vaccines could avert almost 200 000 future deaths 
between 2015 and 2030.7 We believe this outcome was an 
underestimate and our results suggest 489 000 additional 
deaths could be averted from an investment in improved 
post-exposure prophylaxis access. We have taken a more 
detailed approach using a decision tree informed by 
recent and relevant data, and we assume improvements 
in access, health seeking, and compliance.
Key barriers to rabies prevention are the limited supply 
and high costs of post-exposure prophylaxis, which are 
largely borne by patients. A Gavi investment in post-
exposure prophylaxis should displace personal, but not 
government expenditure. Free post-exposure prophylaxis 
provision, with cofinancing between Gavi and national 
governments, would support the drive for universal health 
coverage to achieve the Sustainable Development Goals,35 
and the consensus that rabies prevention should be a free 
public commodity.5 Gavi support would promote use of 
WHO prequalified vaccines and the 1-week intradermal 
regimen, standardise vaccine prices, and improve 
forecasting, procurement, and accountability. Stockouts, 
which are chronic in many rabies-endemic countries, 
could be prevented. Although post-exposure prophylaxis 
is outside the Expanded Programme on Immunization, 
efforts to strengthen this programme (particularly cold 
chain) greatly benefit post-exposure prophylaxis delivery. 
Thus, the potential of Gavi to shape the market, ensuring 
the availability or supply of WHO prequalified vaccines at 
affordable prices could be transformative for rabies 
prevention and would require a modest investment in the 
context of an annual budget in excess of $1 billion for 
vaccine programme disbursements.36
An investment in rabies vaccine in Gavi-eligible 
countries is likely to save many lives at a very low cost per 
death averted. Improving access to post-exposure 
prophylaxis alongside a switch to the newly-recom mended 
intradermal 1-week regimen is feasible because vaccine 
vial requirements do not increase. Moreover, shifting 
costs from bite victims to donors and governments 
overcomes the primary barrier limiting access to life-
saving vaccines and enables more efficient dose-sparing 
practices. To reduce an indefinite and escalating 
requirement for post-exposure prophylaxis, mass dog 
vaccination is essential to control and eliminate rabies in 
the reservoir population.
Contributors
GTE, MRa, CJEM, LB, SFA, SMT, AM, GW, MM, ATr, AO, RMo, BB, 
KH, JC, ZM, AL, KL, AG, JZ, JH, MLa, MLe, RW, JB, NS, GBC, OY, ATa, 
SL, TT, NTTH, LT, SJ, MKS, DHAN, and LK collected and contributed to 
data. CT, KH, FV, RS, MRi, and LK reviewed the literature. CT, KH, 
BA-R, and LK designed the study. KH, FV, RS, RMa, LC, and CT 
developed and implemented the model. NC checked the models. 
KH and CT wrote the first draft of the manuscript. All authors critically 
reviewed the manuscript and interpretation of results. Contributors are 
listed in the appendix.
Declaration of interests
CT reports consulting payments from GlaxoSmithKline in 2013 and an 
honorarium from Sanofi-Pasteur in 2015. LT and SJ are employed by the 
Global Alliance for Rabies Control (GARC), an international non-profit 
organisation aiming to end rabies in every country. DB is the founder 
and former executive director of GARC. JK is employed by Merck Sharpe 
and Dohme Animal Health, a manufacturer of dog rabies vaccines. 
ATa declares that the Institut Pasteur in Cambodia received 
non-nominative grants from Sanofi to develop rabies prevention 
materials for dog bite patients and World Rabies Day information 
campaigns for the general public. JZ, NC, MLa, JH, and MLe were partly 
supported by WHO, Gavi, the Vaccine Alliance, and the Swiss National 
Science Foundation for this work. LB was employed by GlaxoSmithKline 
Vaccines until May, 2016. All other authors declare no competing 
interests. The authors alone are responsible for the views expressed in 
this Article, which do not necessarily represent the views, decisions, or 
policies of the institutions with which the authors are affiliated.
Acknowledgments
This work is supported by a grant from WHO to the Universities of 
Glasgow and Cambridge. KH and RMa were supported by the Wellcome 
Trust (207569/Z/17/Z), with additional funding for RMa from 
Stuart H Leckie. The Wellcome Trust through Afrique One ASPIRE also 
supported MLe and several unpublished studies and the UBS Optimus 
Foundation supported LT and SJ. The Gavi learning agenda on rabies 
supported many of the unpublished studies that contributed data. The 
Swiss National Science Foundation supported MLa. The Institut Pasteur 
financed studies in Cambodia.
References
1 Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the 
burden of rabies in Africa and Asia. Bull World Health Organ 2005; 
83: 360–68.
Articles
www.thelancet.com/infection   Vol 19   January 2019 111
2 Hampson K, Coudeville L, Lembo T, et al. Estimating the global 
burden of endemic canine rabies. PLoS Negl Trop Dis 2015; 
9: e0003786.
3 WHO. Zero by 30: the global strategic plan to end human deaths 
from dog-mediated rabies by 2030. http://www.who.int/rabies/
resources/9789241513838/en/ (accessed Nov 9, 2018).
4 WHO. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 
2018; 16: 201–20.
5 WHO, Food and Agriculture Organization, World Organization for 
Animal Health, Global Alliance for Rabies Control. Zero by 30: 
the global strategic plan to end human deaths from dog-mediated 
rabies by 2030. http://www.who.int/rabies/United_against_Rabies/
en/ (accessed Oct 29, 2018).
6 WHO Strategic Advisory Group of Experts Working Group on 
rabies vaccines and rabies immunoglobulins (July 2016 to 
April 2018). Immunizations, vaccines and biologicals. 
http://www.who.int/immunization/policy/sage/sage_wg_rabies_
jul2016/en/ (accessed Oct 30, 2018).
7 Gavi—The Vaccine Alliance. Rabies vaccine investment strategy. 
http://www.gavi.org/about/strategy/vaccine-investment-strategy/ 
(accessed Oct 30, 2018).
8 Taylor L, Abela-Ridder B, Fahrion A, Hampson K, Nel LH. 
Difficulties in estimating the human burden of canine rabies. 
Acta Trop 2017; 165: 133–40.
9 Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and 
transparent health estimates reporting: the GATHER statement. 
PLoS Med 2016; 13: e1002056.
10 Husereau D, Drummond M, Petrou S, et al. Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) statement. 
Int J Technol Assess Health Care 2013; 29: 117–22.
11 Lembo T, Hampson K, Kaare MT, et al. The feasibility of canine 
rabies elimination in Africa: dispelling doubts with data. 
Plos Neglected Tropical Diseases 2010; 4: e626.
12 Undurraga EA, Meltzer MI, Tran CH, et al. Cost-effectiveness 
evaluation of a novel integrated bite case management program for 
the control of human rabies, Haiti 2014–2015. Am JTrop Med Hyg 2017; 
96: 1307–17.
13 Etheart MD, Kligerman M, Augustin PD, et al. Effect of counselling 
on health-care-seeking behaviours and rabies vaccination adherence 
after dog bites in Haiti, 2014–15: a retrospective follow-up survey. 
Lancet Glob Health 2017; 5: e1017–25.
14 UN World Population Prospects. 2017 https://esa.un.org/unpd/
wpp/Download/Standard/Population/ (accessed Oct 30, 2018).
15 World Bank Development Indicators. http://wdi.worldbank.org/
table/3.12 (accessed Oct 30, 2018).
16 Department of Information, Evidence and Research. 
WHO methods and data sources for global burden of disease 
estimates 2000–2015. Geneva: World Health Organization, 2017.
17 WHO. Health economics. Health delivery costs. http://www.who.
int/choice/cost-effectiveness/inputs/health_service/en/ 
(accessed Oct 30, 2018).
18 Changalucha J, Grieve E, Lushasi K, et al. The need to improve access 
to rabies post-exposure vaccines: lessons from Tanzania. Vaccine 2018; 
published online Oct 8. DOI:10.1016/j.vaccine.2018.08.086.
19 Beyene TJ, Mourits MCM, Kidane AH, Hogeveen H. Estimating the 
burden of rabies in Ethiopia by tracing dog bite victims. 
PLoS One 2018; 13: e0192313.
20 Hampson K, Abela-Ridder B, Brunker K, et al. Surveillance to 
establish elimination of transmission and freedom from 
dog-mediated rabies. BioRxiv 2016; published online Dec 31. 
DOI:https://doi.org/10.1101/096883.
21 Hampson K, Abela-Ridder B, Bharti OK, et al. Modelling to inform 
prophylaxis regimens to prevent human rabies. Vaccine (in press).
22 Griffiths UK, Korczak VS, Ayalew D, Yigzaw A. Incremental system 
costs of introducing combined DTwP-hepatitis B-Hib vaccine into 
national immunization services in Ethiopia. Vaccine 2009; 
27: 1426–32.
23 Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness 
analysis for national-level priority-setting in the health sector. 
Cost Eff Resour Alloc 2003; 1: 8.
24 Baltazard M, Ghodssi M. Prevention of human rabies; treatment of 
persons bitten by rabid wolves in Iran. Bull World Health Organ 1954; 
10: 797–803.
25 Tarantola A, Ly S, Chan M, et al. Intradermal rabies post-exposure 
prophylaxis can be abridged with no measurable impact on clinical 
outcome in Cambodia, 2003–2014. Vaccine (in press).
26 Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007; 
25: 7605–09.
27 WHO. WHO expert consultation on rabies, third report. World 
Health Organ Tech Rep Ser 2018; 1021: 1–195.
28 Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of 
female human papillomavirus vaccination in 179 countries: 
a PRIME modelling study. Lancet Glob Health 2014; 2: e406–14.
29 Mindekem R, Lechenne MS, Naissengar KS, et al. Cost description 
and comparative cost efficiency of post-exposure prophylaxis and 
canine mass vaccination against rabies in N’Djamena, Chad. 
Front Vet Sci 2017; 4: 38.
30 Cleaveland S, Kaare M, Tiringa P, Mlengeya T, Barrat J. A dog 
rabies vaccination campaign in rural Africa: impact on the 
incidence of dog rabies and human dog-bite injuries. Vaccine 2003; 
21: 1965–73.
31 Townsend SE, Sumantra IP, Pudjiatmoko, et al. Designing 
programs for eliminating canine rabies from islands: Bali, 
Indonesia as a case study. PLos Negl Trop Dis 2013; 7: e2372.
32 Zinsstag J, Lechenne M, Laager M, et al. Vaccination of dogs in an 
African city interrupts rabies transmission and reduces human 
exposure. Sci Transl Med 2017; 9: eaaf6984.
33 Del Rio Vilas VJ, Freire de Carvalho MJ, Vigilato MAN, et al. 
Tribulations of the last mile: sides from a regional program. 
Front Vet Sci 2017; 4: 4.
34 Fitzpatrick MC, Hampson K, Cleaveland S, et al. Cost-effectiveness 
of canine vaccination to prevent human rabies in rural Tanzania. 
Ann Intern Med 2014; 160: 91–100.
35 Halliday JEB, Hampson K, Hanley N, et al. Driving improvements 
in emerging disease surveillance through locally-relevant capacity 
strengthening. Science 2017; 357: 146–48.
36 Gavi, the Vaccine Alliance. Financial reports. http://www.gavi.org/
funding/financial-reports/ (accessed Oct 30, 2018).
